Logo image of EVOK

EVOKE PHARMA INC (EVOK) Stock Fundamental Analysis

USA - NASDAQ:EVOK - US30049G3020 - Common Stock

5.17 USD
-0.01 (-0.19%)
Last: 9/12/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to EVOK. EVOK was compared to 195 industry peers in the Pharmaceuticals industry. EVOK has a bad profitability rating. Also its financial health evaluation is rather negative. EVOK is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

EVOK had negative earnings in the past year.
EVOK had a negative operating cash flow in the past year.
EVOK had negative earnings in each of the past 5 years.
EVOK had a negative operating cash flow in each of the past 5 years.
EVOK Yearly Net Income VS EBIT VS OCF VS FCFEVOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

With a Return On Assets value of -33.51%, EVOK perfoms like the industry average, outperforming 47.18% of the companies in the same industry.
EVOK has a worse Return On Equity (-123.04%) than 64.10% of its industry peers.
Industry RankSector Rank
ROA -33.51%
ROE -123.04%
ROIC N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVOK Yearly ROA, ROE, ROICEVOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

EVOK has a better Gross Margin (96.63%) than 97.95% of its industry peers.
EVOK's Gross Margin has improved in the last couple of years.
EVOK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
EVOK Yearly Profit, Operating, Gross MarginsEVOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

2

2. Health

2.1 Basic Checks

EVOK has more shares outstanding than it did 1 year ago.
EVOK has less shares outstanding than it did 5 years ago.
The debt/assets ratio for EVOK has been reduced compared to a year ago.
EVOK Yearly Shares OutstandingEVOK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EVOK Yearly Total Debt VS Total AssetsEVOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -11.04, we must say that EVOK is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of EVOK (-11.04) is worse than 70.26% of its industry peers.
EVOK has a Debt/Equity ratio of 1.14. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.14, EVOK is doing worse than 74.87% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF N/A
Altman-Z -11.04
ROIC/WACCN/A
WACCN/A
EVOK Yearly LT Debt VS Equity VS FCFEVOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 1.37 indicates that EVOK should not have too much problems paying its short term obligations.
EVOK has a worse Current ratio (1.37) than 70.77% of its industry peers.
A Quick Ratio of 1.32 indicates that EVOK should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.32, EVOK is not doing good in the industry: 66.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.32
EVOK Yearly Current Assets VS Current LiabilitesEVOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

EVOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.30%, which is quite impressive.
The Revenue has grown by 70.08% in the past year. This is a very strong growth!
The Revenue has been growing by 84.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)83.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)70.08%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%47.08%

3.2 Future

The Earnings Per Share is expected to grow by 34.84% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 52.59% on average over the next years. This is a very strong growth
EPS Next Y55.96%
EPS Next 2Y46.42%
EPS Next 3Y34.84%
EPS Next 5YN/A
Revenue Next Year57.78%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EVOK Yearly Revenue VS EstimatesEVOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
EVOK Yearly EPS VS EstimatesEVOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -100 -200 -300

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

EVOK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 7.92, which indicates a rather cheap valuation of EVOK.
Based on the Price/Forward Earnings ratio, EVOK is valued cheaper than 90.26% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.73. EVOK is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.92
EVOK Price Earnings VS Forward Price EarningsEVOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVOK Per share dataEVOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
EVOK's earnings are expected to grow with 34.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.42%
EPS Next 3Y34.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVOK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOKE PHARMA INC

NASDAQ:EVOK (9/12/2025, 8:00:02 PM)

5.17

-0.01 (-0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners16.93%
Inst Owner Change-4.2%
Ins Owners1.18%
Ins Owner Change0.26%
Market Cap8.07M
Analysts82.86
Price Target18.36 (255.13%)
Short Float %4.06%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-77.06%
Min EPS beat(2)-102.61%
Max EPS beat(2)-51.52%
EPS beat(4)1
Avg EPS beat(4)-73.67%
Min EPS beat(4)-142.52%
Max EPS beat(4)1.96%
EPS beat(8)3
Avg EPS beat(8)-37.13%
EPS beat(12)6
Avg EPS beat(12)-22.72%
EPS beat(16)8
Avg EPS beat(16)-19.86%
Revenue beat(2)0
Avg Revenue beat(2)-6.01%
Min Revenue beat(2)-8.93%
Max Revenue beat(2)-3.1%
Revenue beat(4)1
Avg Revenue beat(4)-7.34%
Min Revenue beat(4)-22.51%
Max Revenue beat(4)5.18%
Revenue beat(8)3
Avg Revenue beat(8)-5.48%
Revenue beat(12)5
Avg Revenue beat(12)-2.75%
Revenue beat(16)6
Avg Revenue beat(16)1.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-221.43%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-94.06%
EPS NY rev (3m)-94.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.28%
Revenue NY rev (3m)-0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.92
P/S 0.63
P/FCF N/A
P/OCF N/A
P/B 1.84
P/tB 1.84
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)0.65
Fwd EY12.63%
FCF(TTM)-2.32
FCFYN/A
OCF(TTM)-2.32
OCFYN/A
SpS8.2
BVpS2.8
TBVpS2.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.51%
ROE -123.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.63%
FCFM N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
F-Score5
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.32
Altman-Z -11.04
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y55.96%
EPS Next 2Y46.42%
EPS Next 3Y34.84%
EPS Next 5YN/A
Revenue 1Y (TTM)70.08%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%47.08%
Revenue Next Year57.78%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A
EBIT growth 1Y14.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y43.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y43.86%
OCF growth 3YN/A
OCF growth 5YN/A